Long lasting synthetic exendin-4 peptide conjugates
View Patent ↗Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
1. A compound according to the following formula:
2. A pharmaceutical composition comprising a compound according to the following formula:
in association with a physiologically acceptable medium.
3. A method of making a conjugate comprising the step of reacting a compound according to the following formula:
with albumin to form a covalent bond therebetween.
4. The method of claim 3 , wherein said reacting occurs between a compound according to the following formula:
and cysteine 34 thiol of albumin.
5. The method of claim 2 , wherein the reacting step occurs in vivo.
6. The method of claim 3 , wherein the reacting step occurs ex vivo.
7. The method of claim 3 , wherein the albumin is human serum albumin.
8. The conjugate produced by the method of claim 3 .
9. The conjugate produced by the method of claim 4 .
10. The conjugate produced by the method of claim 7 .
11. A pharmaceutical composition comprising the conjugate of claim 8 in association with a physiologically acceptable medium.
12. A pharmaceutical composition comprising the conjugate of claim 9 in association with a physiologically acceptable medium.
13. A pharmaceutical composition comprising the conjugate of claim 10 in association with a physiologically acceptable medium.
14. The method of claim 4 , wherein the albumin is serum albumin.
15. The method of claim 14 , wherein the reacting step occurs ex vivo.
16. The method of claim 4 , wherein the albumin is human serum albumin.
17. The method of claim 16 , wherein the reacting step occurs ex vivo.
18. The conjugate produced by claim 15 .
19. The conjugate produced by claim 15 .
20. The conjugate produced by claim 17 .
21. A pharmaceutical composition comprising the conjugate of claim 18 in association with a physiologically acceptable medium.
22. A pharmaceutical composition comprising the conjugate of claim 19 in association with a physiologically acceptable medium.
23. A pharmaceutical composition comprising the conjugate of claim 20 in association with a physiologically acceptable medium.